- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07615634
The Efficacy and Safety of Female PRP Co-incubation With Sperm During (IUI) Cycles
The Efficacy and Safety of Female Autologous Platelet-Rich Plasma (PRP) Co-incubation With Sperm During the Intrauterine Insemination (IUI) Cycles: A Prospective, Randomized Controlled Trial
The investigators hypothesize that infertility patients undergoing IUI who receive female autologous platelet-rich plasma (PRP) co-incubation with husband's sperm would have higher clinical pregnancy rate.
Primary outcome:
To compare the incidence of clinical pregnancy outcome in those infertility patients undergoing IUI with female PRP co-incubation with husband's sperm group and non-PRP group.
Secondary outcomes:
- To evaluate the post-culture sperm parameters between the intervention group and control group
- To evaluate the IUI parameter between the intervention group and control group
- To evaluate the safeness between the female PRP co-incubation with husband's sperm in the IUI group and non-PRP group, including potential infection rate or other pregnancy outcomes such as miscarriage, multiple pregnancy, ectopic pregnancy and molar pregnancy
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Hong Kong, Kina
- The Chinese University of Hong Kong
-
Kontakt:
- Chung PW Jacqueline
- Telefonnummer: 35051537
- E-post: jacquelinechung@cuhk.edu.hk
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Patients who were eligible for IUI cycles in Assissted Reproduction Technolog unit, Prince of Wales Hospital
- Female patients aged >18 years old and < 42 years old
- BMI < 30 kg/m2
Exclusion Criteria:
- Concurrent administration of other agents such as prednisolone, intravenous immunoglobulin, or G-CSF
- Administration of anticoagulants or NSAIDs at least 7 days before PRP infuse
- Drug addiction
- Untreated urinary tract infection
- Underlying uncontrolled diabetes or hypertension, chromosomal or uterine abnormalities, genetic, hematologic, immunological, or endocrine disorders
- Chronic disease, systemic disease or cancers
- Blood diseases (sepsis, thrombocytopenia)
- Poor sperm samples (raw sample TMS <5 x 106)
- Smoking and drinking alcoholic beverages on the day of IUI
- Fever on the day of IUI
- Redduse or incomplete in obtaining informed consent
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Sham Comparator: non-PRP group (control group)
non-PRP group (control group): non-PRP in the conventional IUI
|
non-PRP group (control group): non-PRP in the conventional IUI
|
|
Experimentell: PRP group (intervention group)
PRP group (intervention group): female PRP co-incubation with husband's sperm in the IUI
|
PRP group (intervention group): female PRP co-incubation with husband's sperm in the IUI
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinical pregnancy
Tidsram: 6 weeks gestation and ultrasound scanning will be performed to confirm at least one gestational sac around 2 to 3 months after IUI
|
To determine the rate of clinical pregnancy outcome in subjects undergoing IUI with PRP co-incubation with husband's sperm group than non-PRP group.
|
6 weeks gestation and ultrasound scanning will be performed to confirm at least one gestational sac around 2 to 3 months after IUI
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sperm motility
Tidsram: after 30 minutes of co-culture
|
To evaluate the Sperm motility between the intervention group and control group
|
after 30 minutes of co-culture
|
|
beta hCG positivity
Tidsram: up to 24 weeks of IUI
|
To evaluate the rate of beta hCG positivity between the intervention group and control group
|
up to 24 weeks of IUI
|
|
Infection or other complications
Tidsram: up to 24 weeks of IUI
|
To evaluate the rate of potential infection in the intervention group and control group
|
up to 24 weeks of IUI
|
|
Miscarriage
Tidsram: up to 24 weeks of IUI
|
To determine to the rate miscarriage outcome in the intervention group and control group
|
up to 24 weeks of IUI
|
|
Multiple pregnancy
Tidsram: up to 24 weeks of IUI
|
To determine to the rate of multiple pregnancy in the intervention group and control group
|
up to 24 weeks of IUI
|
|
Ectopic pregnancy
Tidsram: up to 24 weeks of IUI
|
To determine to the rate of ectopic pregnancy in the intervention group and control group
|
up to 24 weeks of IUI
|
|
Molar pregnancy
Tidsram: up to 24 weeks of IUI
|
To determine to the rate of molar pregnancy in the intervention group and control group
|
up to 24 weeks of IUI
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026.182
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .